Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'

Authors

Jesse Veenstra, Henry Ford HealthFollow
Jie Wang, Henry Ford HealthFollow
Kathleen Maksimowicz-McKinnon, Henry Ford HealthFollow
Tingting Liu, Henry Ford HealthFollow
Bobby Zuniga, Henry Ford HealthFollow
Iltefat H. Hamzavi, Henry Ford HealthFollow
Li Zhou, Henry Ford HealthFollow
Qing-Sheng Mi, Henry Ford HealthFollow

Recommended Citation

Veenstra J, Wang J, McKinnon-Maksimowicz K, Liu T, Zuniga B, Hamzavi I, Zhou L, and Mi QS. Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'. Ann Rheum Dis 2021.

Document Type

Article

Publication Date

6-10-2021

Publication Title

Annals of the rheumatic diseases

PubMed ID

34112654

ePublication

ePub ahead of print